Product Description
SeaGen is developing SGN-30, an intravenously administered recombinant anti-CD30 monoclonal antibody for the potential treatment of Hodgkin's disease, certain non-Hodgkin's lymphomas, specific leukemia, and immunological diseases such as multiple sclerosis and systemic lupus erythematosus. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/16610770/)
Mechanisms of Action: CD30 Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: Eastern America
Company Founding Year: 1849
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Lymphoma, B-Cell|Hodgkin Lymphoma|T-Cell Cutaneous Lymphoma|Large-Cell Anaplastic Lymphoma|Sarcoma, Kaposi|Lymphoma, Non-Hodgkin|Lymphomatoid Papulosis|Primary Cutaneous Anaplastic Large Cell Lymphoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2005-003369-17 |
2005-003369-17 | P2 |
Completed |
Hodgkin Lymphoma |
2025-01-27 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT00365274 |
NCI-2009-00162 | P2 |
Terminated |
Lymphoma, Non-Hodgkin|Large-Cell Anaplastic Lymphoma |
2010-05-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT00354107 |
NCI-2009-00407 | P2 |
Terminated |
Large-Cell Anaplastic Lymphoma|Lymphoma, Non-Hodgkin |
2010-01-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT00337194 |
NCI-2012-02822 | P2 |
Completed |
Hodgkin Lymphoma |
2008-09-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT00099255 |
SG030-0004 | P2 |
Completed |
Large-Cell Anaplastic Lymphoma|Primary Cutaneous Anaplastic Large Cell Lymphoma|Lymphoma, Non-Hodgkin|Lymphomatoid Papulosis |
2007-02-01 |
2020-10-28 |
Primary Endpoints|Treatments |
|
NCT00079755 |
SG030-0003 | P2 |
Completed |
Lymphoma, Non-Hodgkin|Large-Cell Anaplastic Lymphoma |
2006-12-01 |
2020-10-28 |
Treatments |
|
2004-000607-17 |
- | P2 |
Completed |
Hodgkin Lymphoma |
2006-09-20 |
2022-03-12 |
Treatments |
|
NCT00051597 |
SG030-0002 | P2 |
Completed |
Lymphoma, B-Cell|Hodgkin Lymphoma|T-Cell Cutaneous Lymphoma|Sarcoma, Kaposi |
None |
2020-10-28 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/22/2021 |
News Article |
Gensource Announces Completion of NI 43-101 Technical Report Summarizing the Tugaske Project |